https://nova.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 The MSReactor computerized cognitive battery correlates with the processing speed test in relapsing-remitting multiple sclerosis https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:39575 Wed 27 Jul 2022 14:43:55 AEST ]]> A polymorphism in the HLA-DPB1 gene is associated with susceptibility to multiple sclerosis https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:13674 Wed 24 Jun 2020 12:51:30 AEST ]]> Polymorphisms in the receptor tyrosine kinase MERTK gene are associated with multiple sclerosis susceptibility https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:13672 Wed 11 Apr 2018 16:23:10 AEST ]]> Modeling the cumulative genetic risk for multiple sclerosis from genome-wide association data https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:13671 Wed 11 Apr 2018 16:06:02 AEST ]]> Comparing genotyping algorithms for Illumina's Infinium whole-genome SNP BeadChips https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:13673 Wed 11 Apr 2018 15:24:43 AEST ]]> Interleukin-6 gene promoter-572 C allele may play a role in rate of disease progression in multiple sclerosis https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:24220 A and −174 G>C) correlate with MS susceptibility, but with varying results. In the present study, we analyzed these polymorphisms, together with an additional polymorphism (−572 G>C) in 279 healthy controls and 509 patients with MS. We found no significant differences between MS patients and healthy controls for the different −597 or −174 IL6 promoter alleles or genotypes. There was a slight reduction in the percentage of individuals with MS who carried a C allele at position −572, although this was not significant after correction for multiple comparisons. Interestingly, however, the −572 C allele showed a significant correlation with the MS severity score, suggesting a possible role in disease progression.]]> Wed 11 Apr 2018 15:18:27 AEST ]]> Not all roads lead to the immune system: the genetic basis of multiple sclerosis severity https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:52120 Thu 28 Sep 2023 15:04:45 AEST ]]> HLA-DRB1*15:01 and the MERTK Gene Interact to Selectively Influence the Profile of MERTK-Expressing Monocytes in Both Health and MS https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:55006 Thu 28 Mar 2024 13:52:11 AEDT ]]> Genome-wide association study identifies new multiple sclerosis susceptibility loci on chromosomes 12 and 20 https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:7518 Sat 24 Mar 2018 08:38:28 AEDT ]]> Genome-wide meta-analysis identifies novel multiple sclerosis susceptibility loci https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:12845 T at 3p24.1 (odds ratio [OR], 1.17; p = 1.6 × 10−8) near EOMES, rs2150702G in the second intron of MLANA on chromosome 9p24.1 (OR, 1.16; p = 3.3 × 10−8), and rs6718520A in an intergenic region on chromosome 2p21, with THADA as the nearest flanking gene (OR, 1.17; p = 3.4 × 10−8). The 3 new loci do not have a strong cis effect on RNA expression in PBMCs. Ten other susceptibility loci had a suggestive p < 1 × 10−6, some of these loci have evidence of association in other inflammatory diseases (ie, IL12B, TAGAP, PLEK, and ZMIZ1). Interpretation: We have performed a meta-analysis of GWAS in MS that more than doubles the size of previous gene discovery efforts and highlights 3 novel MS susceptibility loci. These and additional loci with suggestive evidence of association are excellent candidates for further investigations to refine and validate their role in the genetic architecture of MS.]]> Sat 24 Mar 2018 08:17:22 AEDT ]]> Latitudinal variation in incidence and type of first central nervous system demyelinating events https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:10630 Sat 24 Mar 2018 08:13:48 AEDT ]]> Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: An Australian and New Zealand perspective Part 2 New and emerging therapies and their efficacy https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:18887 Sat 24 Mar 2018 08:03:12 AEDT ]]> Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: An Australian and New Zealand perspective Part 1 Historical and established therapies https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:18886 Sat 24 Mar 2018 08:03:11 AEDT ]]> Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: An Australian and New Zealand perspective Part 3 Treatment practicalities and recommendations https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:18888 Sat 24 Mar 2018 08:03:11 AEDT ]]> Closing the case of APOE in multiple sclerosis: no association with disease risk in over 29 000 subjects https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:25354 Sat 24 Mar 2018 07:24:42 AEDT ]]> A new era in the treatment of multiple sclerosis https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:23863 Sat 24 Mar 2018 07:12:10 AEDT ]]> A rare P2X7 variant Arg307Gln with absent pore formation function protects against neuroinflammation in multiple sclerosis https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:24704 85% loss of 'pore' function of the P2X7 receptor measured by ATP-induced ethidium uptake. Analysis shows Arg307Gln always occurred with 270His suggesting a single 307Gln-270His haplotype which confers dominant negative effects on P2X7 function and protection against MS. Modelling based on the homologous zP2X4 receptor showed Arg307 is located in a region rich in basic residues located only 12Å from the ligand binding site. Our data show the protective effect against MS of a rare genetic variant of P2RX7 with heterozygotes showing near absent proinflammatory 'pore' function.]]> Sat 24 Mar 2018 07:10:52 AEDT ]]>